Artiva Biotherapeutics, Inc.
corporate_fare Company Profile
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ARTV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for ARTV spans 10-Q, 8-K, SCHEDULE 13D/A, 4.
Recent high-impact activity:
- Artiva 10-Q: $319M Cash After AlloNK Wind-Down, $27-35M Restructuring Costs
- Artiva Halts AlloNK After Two Patient Deaths, Cuts 94% of Staff, Pursues Strategic Alternatives
- Artiva Scraps Lead AlloNK Program After Grade 5 Safety Events, Cuts 94% of Staff
- AlloNK Shows Strong Sjögren Efficacy and Clean Safety in Phase 2a
- Artiva Biotherapeutics Q2 2026: RMAT Designation, Phase 3 on Track, Cash Runway into 2029
Financial Snapshot
Short Interest & Short Volume
1.81 days to coverFINRA reported short interest of 2,953,973 shares in ARTV as of the October 30, 2026 settlement, a 7.9% increase from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 69.6% of ARTV volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ARTV, detected from its recent SEC filings.
$400M Shelf Registration Filed · $100M ATM Program Included
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →